These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12168823)

  • 21. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
    Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
    Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.
    Downs-Kelly E; Mendelin JE; Bennett AE; Castilla E; Henricks WH; Schoenfield L; Skacel M; Yerian L; Rice TW; Rybicki LA; Bronner MP; Goldblum JR
    Am J Gastroenterol; 2008 Sep; 103(9):2333-40; quiz 2341. PubMed ID: 18671819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
    Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
    Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barrett's esophagus: pathologic considerations and implications for treatment.
    Rice TW; Mendelin JE; Goldblum JR
    Semin Thorac Cardiovasc Surg; 2005; 17(4):292-300. PubMed ID: 16428035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia.
    Chen X; Lechago J; Ertan A; Ergun G; Verm R; Bridges M; Johnson C; Woods K; Meriano F; Chirala M; Younes M
    Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):30-3. PubMed ID: 14744729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
    Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
    Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus.
    Younes M; Lechago J; Ertan A; Finnie D; Younes A
    Hum Pathol; 2000 Apr; 31(4):434-8. PubMed ID: 10821489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
    Asthana N; Mandich D; Ligato S
    Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What's new in columnar lined esophagus (Barrett's metaplasia)?
    Tadiparthi R; Bansal A; Sharma P
    Curr Opin Gastroenterol; 2008 Jul; 24(4):516-20. PubMed ID: 18622169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.
    Tselepis C; Perry I; Dawson C; Hardy R; Darnton SJ; McConkey C; Stuart RC; Wright N; Harrison R; Jankowski JA
    Oncogene; 2002 Sep; 21(39):6071-81. PubMed ID: 12203119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
    Lim CH; Treanor D; Dixon MF; Axon AT
    Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
    Endzinas Z; Mickevicius A; Kiudelis M
    Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system).
    Sharma VK; Kim HJ; Das A; Dean P; DePetris G; Fleischer DE
    Endoscopy; 2008 May; 40(5):380-7. PubMed ID: 18459074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor.
    Haigh CR; Attwood SE; Thompson DG; Jankowski JA; Kirton CM; Pritchard DM; Varro A; Dimaline R
    Gastroenterology; 2003 Mar; 124(3):615-25. PubMed ID: 12612900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma.
    Weston AP; Sharma P
    Am J Gastroenterol; 2002 Dec; 97(12):2998-3006. PubMed ID: 12492182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
    Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
    Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.
    Koss K; Harrison RF; Gregory J; Darnton SJ; Anderson MR; Jankowski JA
    J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
    Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.